111 related articles for article (PubMed ID: 25998402)
1. Thiopurine Resistance in Childhood ALL Is Mediated by PRPS1 Mutations.
Cancer Discov; 2015 Jul; 5(7):693. PubMed ID: 25998402
[TBL] [Abstract][Full Text] [Related]
2. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
Li B; Li H; Bai Y; Kirschner-Schwabe R; Yang JJ; Chen Y; Lu G; Tzoneva G; Ma X; Wu T; Li W; Lu H; Ding L; Liang H; Huang X; Yang M; Jin L; Kang H; Chen S; Du A; Shen S; Ding J; Chen H; Chen J; von Stackelberg A; Gu L; Zhang J; Ferrando A; Tang J; Wang S; Zhou BB
Nat Med; 2015 Jun; 21(6):563-71. PubMed ID: 25962120
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Mediated Induction of Relapse-Specific
Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
[TBL] [Abstract][Full Text] [Related]
4. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
[TBL] [Abstract][Full Text] [Related]
5. Mutant PRPS1: a new therapeutic target in relapsed acute lymphoblastic leukemia.
Mullighan CG
Nat Med; 2015 Jun; 21(6):553-4. PubMed ID: 26046573
[No Abstract] [Full Text] [Related]
6. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
[TBL] [Abstract][Full Text] [Related]
7. Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-Fluorouracil.
Wang D; Chen Y; Fang H; Zheng L; Li Y; Yang F; Xu Y; Du L; Zhou BS; Li H
J Cell Mol Med; 2018 Dec; 22(12):6202-6212. PubMed ID: 30255549
[TBL] [Abstract][Full Text] [Related]
8. Thioguanine versus mercaptopurine in childhood ALL.
Stanulla M; Schünemann HJ
Lancet; 2006 Oct; 368(9544):1304-6. PubMed ID: 17046444
[No Abstract] [Full Text] [Related]
9. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.
Evensen NA; Madhusoodhan PP; Meyer J; Saliba J; Chowdhury A; Araten DJ; Nersting J; Bhatla T; Vincent TL; Teachey D; Hunger SP; Yang J; Schmiegelow K; Carroll WL
Haematologica; 2018 May; 103(5):830-839. PubMed ID: 29449434
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.
Coulthard SA; Matheson EC; Hall AG; Hogarth LA
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1385-91. PubMed ID: 15571264
[TBL] [Abstract][Full Text] [Related]
11. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.
Karas-Kuzelicki N; Mlinaric-Rascan I
Pharmacogenomics; 2009 Aug; 10(8):1309-22. PubMed ID: 19663675
[TBL] [Abstract][Full Text] [Related]
12. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of
Moriyama T; Liu S; Li J; Meyer J; Zhao X; Yang W; Shao Y; Heath R; Hnízda A; Carroll WL; Yang JJ
Mol Cancer Ther; 2019 Oct; 18(10):1887-1895. PubMed ID: 31358663
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes.
Ebbesen MS; Nersting J; Jacobsen JH; Frandsen TL; Vettenranta K; Abramsson J; Wesenberg F; Schmiegelow K
J Clin Pharmacol; 2013 Jun; 53(6):670-4. PubMed ID: 23585236
[No Abstract] [Full Text] [Related]
16. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy.
Warren DJ; Andersen A; Slørdal L
Cancer Res; 1995 Apr; 55(8):1670-4. PubMed ID: 7712473
[TBL] [Abstract][Full Text] [Related]
18. Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.
Brouwer C; Vogels-Mentink TM; Keizer-Garritsen JJ; Trijbels FJ; Bökkerink JP; Hoogerbrugge PM; van Wering ER; Veerman AJ; De Abreu RA
Clin Chim Acta; 2005 Nov; 361(1-2):95-103. PubMed ID: 15990089
[TBL] [Abstract][Full Text] [Related]
19. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.
Dervieux T; Chu Y; Su Y; Pui CH; Evans WE; Relling MV
Clin Chem; 2002 Jan; 48(1):61-8. PubMed ID: 11751539
[TBL] [Abstract][Full Text] [Related]
20. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck CL; Ferrando A
Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
